Johnson & Johnson, which in-licensed Legend's CAR-T technology and is developing a version of its product under the name JNJ-4528, presented data from the Phase Ib/II CARTITUDE-1 study at the ASCO meeting.
Data on multiple CAR-Ts presented at the recent ASCO meeting have raised the prospect of outpatient use of the therapies, which is favorable for reimbursement as well as for patients. But experts pointed to significant infrastructure challenges that centers face.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.